An observational prospective cohort study of naloxone use at witnessed overdoses, Kazakhstan, Kyrgyzstan, Tajikistan, Ukraine.

Paul Dietze, Gilberto Gerra, Vladimir Poznyak, Giovanna Campello, Wataru Kashino, Dzhonbek Dzhonbekov, Tetiana Kiriazova, Danil Nikitin, Assel Terlikbayeva, Dzmitry Krupchanka, Anja Busse

Journal: Bulletin of the World Health Organization 2022;100(3):187-195

PMID: 35261407

Abstract

OBJECTIVE

To determine whether participation in the United Nations Office on Drugs and Crime (UNODC) and the World Health Organization's (WHO) Stop Overdose Safely (S-O-S) take-home naloxone training project in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine resulted in naloxone use at witnessed opioid overdoses.

METHODS

An observational prospective cohort study was performed by recruiting participants in the implementation of the S-O-S project, which was developed as part of the broader S-O-S initiative. Training included instruction on overdose responses and naloxone use. Study participants were followed for 6 months after completing training. The primary study outcome was participants' naloxone use at witnessed overdoses, reported at follow-up.

FINDINGS

Between 400 and 417 S-O-S project participants were recruited in each country. Overall, 84% (1388/1646) of participants were interviewed at 6-month follow-up. The percentage who reported witnessing an overdose between baseline and follow-up was 20% (71/356) in Tajikistan, 33% (113/349) in Kyrgyzstan, 37% (125/342) in Ukraine and 50% (170/341) in Kazakhstan. The percentage who reported using naloxone at their most recently witnessed overdose was 82% (103/125) in Ukraine, 89% (152/170) in Kazakhstan, 89% (101/113) in Kyrgyzstan and 100% (71/71) in Tajikistan.

CONCLUSION

Implementation of the UNODC-WHO S-O-S training project in four low- to middle-income countries resulted in the reported use of take-home naloxone at around 90% of witnessed opioid overdoses. The percentage varied between countries but was generally higher than found in previous studies. Take-home naloxone is particularly important in countries where emergency medical responses to opioid overdoses may be limited.

(c) 2022 The authors; licensee World Health Organization.

Address: Behaviours and Health Risks Program, Burnet Institute, 85 Commercial Rd, Melbourne, VIC, 3004, Australia.; Mental Health Department, AUSL of Parma, Parma, Italy.; Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland.; Drug Prevention and Health Branch, United Nations Office on Drugs and Crime, Vienna, Austria.; Public Organization Prisma, Dushanbe, Tajikistan.; Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.; Global Research Institute Foundation, Bishkek, Kyrgyzstan.; Global Health Research Center of Central Asia, Columbia School of Social Work, Almaty, Kazakhstan.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.